A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus

Authors

  • Poornima R

Keywords:

Metformin monotherapy, non-inferiority study, Teneligliptin and metformin dual therapy, Type 2 Diabetes Mellitus.

Abstract

INTRODUCTION: Diabetes mellitus is a metabolic disorder characterised by hyperglycaemia and abnormalities in simple
carbohydrate, fat, and protein metabolism. Diabetes mellitus control can only be achieved by diet, exercise, regular sleep
pattern then with addition of anti-hyperglycemic drugs like metformin, if glycated hemoglobin (HbA1C) is above 7.0%.
MATERIALS & METHODS: The study period was from April 2019 – September 2019. The total duration of study was 24
weeks. Total 160 patients were screened; among them 100 participants were selected as per the inclusion criteria.
RESULTS: Out of 100 patients, only 91 patients have completed the study. Having perceived so much about the weightage of
monotherapy with metformin, this study revealed the non-inferiority of dual therapy.
CONCLUSION: To conclude dipeptidyl peptidase-4(DPP-4) inhibitor Teneligliptin 20mg OD with Metformin 500mg two
times a day (BD) serves the purpose of enhancing the glycaemic control and stands to be an efficacious treatment of type 2
diabetes mellitus with better compliance and acceptability

Downloads

Published

2022-06-30

Issue

Section

Articles

How to Cite

A Comparative Study of Safety and Efficacy of Metformin Monotherapy Against Teneligliptin and Metformin in Type 2 Diabetes Mellitus. (2022). Journal of Pharmaceutical Negative Results, 13(2), 7-12. https://pnrjournal.com/index.php/home/article/view/195